Azithra, Inc. Expands eligibility for ATR-04 Phase 1/2 clinical trial to include patients with KRAS and MEK inhibitor-induced rash -. Company announcement - FT.com.
Azithra, Inc. Expands eligibility for ATR-04 Phase 1/2 clinical trial to include patients with KRAS and MEK inhibitor-induced rash -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in